Lipanthyl Micronised (Fenofibrate Micronised)

Fenofibrate activates the nuclear receptor peroxisome proliferator‑activated receptor‑alpha (PPARα). This activation up‑regulates genes that enhance fatty‑acid β‑oxidation, suppress hepatic triglyceride synthesis, increase lipoprotein lipase activity, and raise HDL‑cholesterol production, collectively lowering plasma triglycerides and modestly reducing LDL‑cholesterol.

The appropriate dose of Lipanthyl Micronised is determined by the prescribing clinician based on the patient’s lipid profile, renal and hepatic function, and concomitant therapies. Dosage adjustments may be required for special populations, and the medication should be taken exactly as directed on the prescription label.

Safety data for fenofibrate during pregnancy and lactation are limited, and the drug is generally not recommended unless the potential benefit outweighs the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative lipid‑lowering strategies with their healthcare provider.

To request Lipanthyl Micronised, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any required cold‑chain handling—and assistance with import documentation.

Compared with statins, fenofibrate primarily lowers triglycerides and raises HDL‑cholesterol, while statins are more potent at reducing LDL‑cholesterol. Unlike niacin, fenofibrate has a lower incidence of flushing. It is often combined with statins for complementary effects, but clinicians must monitor for increased risk of muscle toxicity when used together.

Lipanthyl Micronised tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Do not refrigerate or freeze the product, and keep it out of reach of children.

The medication is taken orally, usually once daily with a meal to enhance absorption. Patients should swallow the tablet whole with water and follow any specific instructions provided by their prescriber regarding timing relative to other drugs or meals.

The most serious adverse events include rhabdomyolysis, severe liver injury, and acute renal failure. These risks are heightened when fenofibrate is combined with high‑dose statins, cyclosporine, or other agents that affect muscle or liver metabolism. Prompt medical evaluation is required if patients experience unexplained muscle pain, dark urine, jaundice, or sudden changes in kidney function.

Lipanthyl Micronised is contraindicated in patients with known hypersensitivity to fenofibrate or any component of the formulation, in those with severe hepatic impairment, and in individuals with end‑stage renal disease requiring dialysis. Caution is also advised for patients with gallbladder disease or a history of pancreatitis.